Governance & Derivative

Karyopharm Therapeutics Inc. (NasdaqGS: KPTI)

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Karyopharm Therapeutics Inc. (NasdaqGS: KPTI).

On February 22, 2019, the Federal Drug Administration (“FDA”) reported serious flaws in the New Drug Application and the underlying clinical trial data for the Company’s drug, selinexor. Specifically, the FDA detailed that the Company’s clinical trials demonstrated a history of toxicity and limited efficacy findings due to its trial designs and faulted the Company for violating pre-specified trial protocols and guidance when attempting to use “real-world” data observations to bolster its case for approval.

Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period, violating federal securities laws, which remains ongoing.

KSF’s investigation is focusing on whether Karyopharm’s officers and/or directors breached their fiduciary duties to Karyopharm’s shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of Microchip shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (, or fill out the form on this page.